NASDAQ : TNXP
Tonix Pharmaceuticals Holding Corp. — Key statistics
Healthcare · Biotechnology · United States
Last price 5.28 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 90.56M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 87.47M |
| Enterprise Value | -87.49M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 17.15M |
| Shares Outstanding | 17.15M |
| Shares Change (YoY) | +216.89% |
| Shares Change (QoQ) | +21.36% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 39.33% |
| Float | 14.12M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.01 |
| Forward PS | 1.06 |
| PB Ratio | 0.39 |
| P/TBV Ratio | 0.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.61 |
| Quick Ratio | 6.12 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,858.71 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -81.82% |
| Return on Assets (ROA) | -46.84% |
| Return on Invested Capital (ROIC) | -52.74% |
| Return on Capital Employed (ROCE) | -74.08% |
| Weighted Average Cost of Capital (WACC) | 13.96% |
| Revenue Per Employee | $204,944 |
| Profits Per Employee | -$1.12M |
| Employee Count | 142 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 0.81 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.79 |
| 52-Week Price Change | -72.54% |
| 50-Day Moving Average | 9.53 |
| 200-Day Moving Average | 12.47 |
| Relative Strength Index (RSI) | 17.45 |
| Average Volume (20 Days) | 1,063,980 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.94M |
| Short Previous Month | 2.94M |
| Short % of Shares Out | 17.15% |
| Short % of Float | 20.83% |
| Short Ratio (days to cover) | 3.48 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 29.10M |
| Gross Profit | 24.40M |
| Operating Income | -165.43M |
| Pretax Income | -159.67M |
| Net Income | -159.67M |
| EBITDA | -163.30M |
| EBIT | -165.43M |
| Loss Per Share | -$12.49 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 176.23M |
| Total Debt | 1.27M |
| Net Cash | 174.96M |
| Net Cash Per Share | $10.20 |
| Equity (Book Value) | 222.28M |
| Book Value Per Share | 13.24 |
| Working Capital | 172.65M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -152.99M |
| Capital Expenditures | -5.12M |
| Depreciation & Amortization | 2.12M |
| Net Borrowing | n/a |
| Free Cash Flow | -158.11M |
| FCF Per Share | -$9.22 |
Margins
| Measure | Value |
|---|
| Gross Margin | 83.83% |
| Operating Margin | -568.43% |
| Pretax Margin | -548.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -216.89% |
| Shareholder Yield | -216.89% |
| Earnings Yield | -244.87% |
| FCF Yield | -180.76% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $39.00 |
| Price Target Difference | 664.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 140.57% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 5, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.1 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |